Nanopore sequencing sheds a light on the FLT3 gene mutations complexity in acute promyelocytic leukemia

References

• Picharski GL, Andrade DP, Fabro ALMR, et al. The impact of Flt3 gene mutations in acute promyelocytic leukemia: a meta-analysis. Cancers (Basel). 2019;11(9):1311–1314.
   Web of Science ®Google Scholar
• Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United King. Blood. 2001;98(6):1752–1759.
   PubMed Web of Science ®Google Scholar
• Minervini CF, Cumbo C, Orsini P, et al. TP53 gene mutation analysis in chronic lymphocytic leukemia by nanopore MinION sequencing. Diagn Pathol. 2016;11(1):96.
   PubMedGoogle Scholar
• Minervini CF, Cumbo C, Orsini P, et al. Nanopore sequencing in blood diseases: a wide range of opportunities. Front Genet. 2020;11:76. [cited 2020 Aug 5]. Available from: https://pubmed.ncbi.nlm.nih.gov/32140171/.
   PubMed Web of Science ®Google Scholar
• Cumbo C, Impera L, Minervini CF, et al. Genomic BCR-ABL1 breakpoint characterization by a multistrategy approach for “personalized monitoring” of residual disease in chronic myeloid leukemia patients. Oncotarget. 2018;9(13):10978–10986.
   PubMedGoogle Scholar
• Minervini CF, Cumbo C, Orsini P, et al. Mutational analysis in BCR-ABL1 positive leukemia by deep sequencing based on nanopore MinION technology. Exp Mol Pathol. 2017;103(1):33–37.
   PubMed Web of Science ®Google Scholar
• Van Dongen JJM, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13(12):1901–1928.
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Avvisati G, Vignetti M, for the Italian GIMEMA Cooperative Group, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood. 2010;116(17):3171–3179.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Avvisati G, Cicconi L, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol. 2017;35(6):605–612.
   PubMed Web of Science ®Google Scholar
• Gabert J, Beillard E, van der Velden VHJ, et al. Standardization and quality control studies of “real time” quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe against Cancer Program. Leukemia. 2003;17(12):2318–2357.
   PubMed Web of Science ®Google Scholar
• Coccaro N, Zagaria A, Orsini P, et al. RARA and RARG gene downregulation associated with EZH2 mutation in acute promyelocytic-like morphology leukemia. Hum Pathol. 2018;80:82–86.
   PubMed Web of Science ®Google Scholar
• Bagrintseva K, Geisenhof S, Kern R, et al. FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L). Blood. 2005;105(9):3679–3685.
   PubMed Web of Science ®Google Scholar
• Man CH, Fung TK, Ho C, et al. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. Blood [Internet]. 2012;119(22):5133–5143.
   Google Scholar
• Wang LN, Tang YL, Zhang YC, et al. Arsenic trioxide and all-trans-retinoic acid selectively exert synergistic cytotoxicity against FLT3-ITD AML cells via co-inhibition of FLT3 signaling pathways. Leuk Lymphoma. 2017;58(10):2426–2438.
   PubMed Web of Science ®Google Scholar
• Cicconi L, Divona M, Ciardi C, et al. PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy. Leukemia. 2016;30(10):1987–1992.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Lo Coco F, Martín G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96:1247.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. [cited 2020 Sep 28]. Available from: https://pubmed.ncbi.nlm.nih.gov/27895058/.
   PubMed Web of Science ®Google Scholar
• Arreba-Tutusaus P, Mack TS, Bullinger L, et al. Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo [Internet]. Leukemia. 2016;30(5):1220–1225.
   PubMed Web of Science ®Google Scholar
• Liu SB, Dong HJ, Bao XB, et al. Impact of FLT3-ITD length on prognosis of acute myeloid leukemia. Haematologica. 2019;104(1):e9–e12.
   PubMed Web of Science ®Google Scholar
• Murphy KM, Levis M, Hafez MJ, et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagnostics. 2003;5(2):96–102.
   PubMed Web of Science ®Google Scholar
• Schranz K, Hubmann M, Harin E, et al. Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia. Oncotarget. 2018;9(53):30128–30145.
   PubMedGoogle Scholar
• Cumbo C, Minervini CF, Orsini P, et al. Nanopore targeted sequencing for rapid gene mutations detection in acute myeloid leukemia. Genes (Basel). 2019;10(12):1026. [cited 2020 Sep 9]. Available from: https://pubmed.ncbi.nlm.nih.gov/31835432/.
   Web of Science ®Google Scholar